Does Zepbound (tirzepatide) have pharmacokinetic or pharmacodynamic interactions with flecainide, metoprolol, lisinopril, rosuvastatin, montelukast, diltiazem, or fenofibrate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Zepbound (Tirzepatide) Drug Interactions

Zepbound (tirzepatide) does not have direct pharmacokinetic interactions with flecainide, metoprolol, lisinopril, rosuvastatin, montelukast, diltiazem, or fenofibrate, but it can cause clinically significant pharmacodynamic interactions requiring dose adjustments of cardiovascular medications, particularly blood pressure and heart rate medications.

Key Pharmacodynamic Concerns

Blood Pressure Medications (Metoprolol, Lisinopril, Diltiazem)

You must proactively reduce doses of antihypertensive medications when starting tirzepatide. Recent case series demonstrate that tirzepatide causes symptomatic hypotension through multiple mechanisms: direct vasodilation, natriuresis, reduction in extracellular volume, and weight loss 1. Three patients on guideline-directed heart failure therapy developed symptomatic hypotension and acute kidney injury requiring significant medication adjustments after tirzepatide initiation 1.

Practical approach:

  • Monitor blood pressure and volume status closely after each tirzepatide dose escalation
  • Anticipate need to reduce or temporarily hold ACE inhibitors (lisinopril), beta-blockers (metoprolol), and calcium channel blockers (diltiazem)
  • Watch for orthostatic symptoms, dizziness, or signs of dehydration
  • The hypotension risk is highest during the dose escalation phase when gastric emptying effects are most pronounced 2

Cardiac Arrhythmia Medications (Flecainide)

No direct interaction exists between tirzepatide and flecainide. However, tirzepatide can cause cardiac arrhythmias and tachycardia as an adverse effect 2. If symptomatic arrhythmias develop, monitor closely and consider adding beta-blockers 2. The flecainide label notes that beta-blockers can be used concurrently without increased side effects, though additive negative inotropic effects are possible 3.

Statin Therapy (Rosuvastatin, Fenofibrate)

No interaction exists between tirzepatide and rosuvastatin or fenofibrate. Continue these lipid-lowering agents at current doses. The only relevant statin interaction from the evidence involves diltiazem, which you're already asking about separately 4.

If using rosuvastatin with diltiazem concurrently: This combination is reasonable but requires awareness that diltiazem moderately increases statin exposure through CYP3A4 inhibition 4. However, rosuvastatin is not extensively metabolized by CYP3A4, making this interaction less clinically significant than with simvastatin or lovastatin 5.

Montelukast

No interaction exists between tirzepatide and montelukast. Continue at current dose.

Critical Monitoring Parameters

During tirzepatide initiation and dose escalation:

  • Blood pressure (sitting and standing) at each visit
  • Heart rate and rhythm if symptomatic
  • Volume status (weight, edema, orthostatic symptoms)
  • Renal function (creatinine, BUN) especially if on ACE inhibitors or diuretics
  • Signs of dehydration or acute kidney injury

Special Considerations

Gastric Emptying Effects

Tirzepatide causes more profound gastric emptying delay than standard GLP-1 agonists, particularly after the first dose, with subsequent tachyphylaxis 6. This mechanism:

  • Does not affect absorption of the medications you listed (all are well-absorbed regardless of gastric emptying rate)
  • May affect oral contraceptives (not relevant to your question) 6
  • Could theoretically affect warfarin (one case report exists) 7, but none of your listed medications have this concern

Volume Depletion Risk

The most clinically significant issue is volume depletion and hypotension 1. Tirzepatide causes weight loss averaging 15-20% at higher doses 2, which translates to significant fluid shifts and reduced blood pressure. This is not a traditional "drug interaction" but a predictable pharmacodynamic consequence requiring medication adjustment.

Bottom line: Start with anticipatory dose reductions of blood pressure medications (metoprolol, lisinopril, diltiazem) by 25-50% when initiating tirzepatide, then titrate based on blood pressure response. All other medications (flecainide, rosuvastatin, montelukast, fenofibrate) can continue unchanged with routine monitoring.

References

Related Questions

Can loperamide be taken concomitantly with tirzepatide?
Are there any drug interactions between Zepbound (tirzepatide) and Dupixent (dupilumab)?
Can tirzepatide cause hyponatremia, and what is the underlying mechanism?
Can Dupixent (dupilumab) and Zepbound (tirzepatide) be co‑administered, and what are the recommended dosing schedules, potential drug interactions, and monitoring recommendations?
Is there a drug interaction between tirzepatide and aripiprazole (Arilan)?
Which individual has authority to declare a public health emergency that permits the use of unapproved medical products, such as COVID‑19 vaccines?
Why must patients fast for 2–4 hours before a cardiac stress test?
Which of the following disease states have established Healthcare Effectiveness Data and Information Set (HEDIS) measures for comparing institutional performance: peripheral arterial disease, heart failure, chronic kidney disease, or hypertension?
In an adult with type 2 diabetes initiating metformin therapy, how long does it take for fasting blood glucose to begin decreasing?
In a 71-year-old, 50-kg female with anxiety, depression, and hypertension who is found unconscious with hypotension, bradycardia, and a widened QRS interval after an overdose of metoprolol succinate and amlodipine, which initial therapy should be given in addition to an intravenous norepinephrine infusion?
Can the shape of a burr hole enlarge over time in a healthy adult, and under what conditions (e.g., in children, infection, poor wound healing) might it change?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.